Dechra Pharmaceuticals PLC
Advisory
Investec acted as financial adviser, sole broker and bookrunner to Dechra Pharmaceuticals PLC on its £180m equity raise
Our role
Investec acted as financial adviser, sole broker and bookrunner to Dechra Pharmaceuticals PLC on its £180m equity raise to institutional investors, approximately 4.8% of the existing issued ordinary share capital of the Company. The equity raise was for the purposes of funding the acquisition of Piedmont Animal Health, Inc for $210 million (£175 million) in cash and providing balance sheet flexibility to execute on an active acquisition.
The equity raise was significantly over-subscribed with substantial demand from new and existing institutional investors. Investec helped Dechra position the equity story and its compelling acquisition strategy through a targeted investor roadshow to both new and existing institutional investors.
About Dechra Pharmaceuticals PLC
Dechra is a global veterinary pharmaceuticals and related products business. The Company’s expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra is a FTSE 100 business with a market capitalisation of c.£4bn and has been a long-term corporate client of Investec since 2009.
Want to know more?
Find out more about how our Corporate Broking and PLC Advisory team can support you.
View more deals
Discover more deals from our award winning team.